SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
May S.K. Sutherland(Seagen (United States)), Julie A. McEarchern(Seagen (United States)), Patrick Burke(Seagen (United States)), Weiping Zeng(Seagen (United States)), Django Sussman(Seagen (United States)), Scott C. Jeffrey(Seagen (United States)), David W. Meyer(Seagen (United States)), Robert P. Lyon(Seagen (United States)), Irwin D. Bernstein(University of Washington), Kimberly H. Harrington(Fred Hutch Cancer Center), Changpu Yu(Seagen (United States)), Lori Westendorf(Seagen (United States)), Ivan J. Stone(Seagen (United States)), Heather Kostner(Seagen (United States)), Peter D. Senter(North Carolina Central University), Jonathan G. Drachman(Seagen (United States)), Maureen C. Ryan(Seagen (United States)), Kerry Klussman(Seagen (United States)), Dennis R. Benjamin(Seagen (United States)), Roland B. Walter(University of Washington)
Cited by 385
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k